A Phase I Study of MK-0646 in Combination With Cetuximab and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Dalotuzumab (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 16 Oct 2012 Actual end date changed from Nov 2010 to Dec 2010, as reported by ClinicalTrials.gov.
- 20 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.